These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 29404512)

  • 1. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    Hepatol Commun; 2018 Jan; 2(1):48-57. PubMed ID: 29404512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.
    Sookoian S; Pirola CJ
    Aliment Pharmacol Ther; 2018 Jan; 47(1):16-25. PubMed ID: 29083036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects.
    Feldman A; Wernly B; Strebinger G; Eder SK; Zandanell S; Niederseer D; Strasser M; Haufe H; Sotlar K; Paulweber B; Datz C; Aigner E
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):366-373. PubMed ID: 34375373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.
    Ahmed OT; Gidener T; Mara KC; Larson JJ; Therneau TM; Allen AM
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1374-1381.e6. PubMed ID: 34265444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease.
    Biswas S; Vaishnav M; Farooqui N; Aggarwal A; Pathak P; Yadav R; Das P; Elhence A; Goel A; Mishra AK; Shalimar
    Postgrad Med J; 2023 Sep; 99(1176):1094-1103. PubMed ID: 37308443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Younes R; Govaere O; Petta S; Miele L; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; McLeod D; Pareja MJ; Fracanzani AL; Aller R; Rosso C; Ampuero J; Gallego-Durán R; Armandi A; Caviglia GP; Zaki MYW; Liguori A; Francione P; Pennisi G; Grieco A; Birolo G; Fariselli P; Eslam M; Valenti L; George J; Romero-Gómez M; Anstee QM; Bugianesi E
    Gut; 2022 Feb; 71(2):382-390. PubMed ID: 33541866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients.
    Hirose S; Matsumoto K; Tatemichi M; Tsuruya K; Anzai K; Arase Y; Shiraishi K; Suzuki M; Ieda S; Kagawa T
    PLoS One; 2020; 15(11):e0241770. PubMed ID: 33186403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of "indeterminate score" measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia.
    Khayyat YM
    World J Hepatol; 2021 Dec; 13(12):2150-2160. PubMed ID: 35070015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases.
    Weinberg EM; Trinh HN; Firpi RJ; Bhamidimarri KR; Klein S; Durlam J; Watkins S; Reddy KR; Weiss M; Zink RC; Lok AS
    Clin Gastroenterol Hepatol; 2021 May; 19(5):996-1008.e6. PubMed ID: 32629123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?
    Kumar R; Rastogi A; Sharma MK; Bhatia V; Garg H; Bihari C; Sarin SK
    Indian J Endocrinol Metab; 2013 Jul; 17(4):665-71. PubMed ID: 23961483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities.
    Golabi P; Paik JM; Arshad T; Younossi Y; Mishra A; Younossi ZM
    Hepatol Commun; 2020 Aug; 4(8):1136-1148. PubMed ID: 32766474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lean nonalcoholic fatty liver disease: Age-dependent differences in pathology, prognosis, and liver-related events.
    Kawanaka M; Nishino K; Kawada M; Ishii K; Tanikawa T; Katsumata R; Urata N; Nakamura J; Suehiro M; Haruma K; Kawamoto H
    Hepatol Res; 2023 Sep; 53(9):829-843. PubMed ID: 37118869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease.
    Charatcharoenwitthaya P; Karaketklang K; Aekplakorn W
    J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2393-2404. PubMed ID: 36017777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in lean NAFLD.
    Xu R; Pan J; Zhou W; Ji G; Dang Y
    Biomed Pharmacother; 2022 Sep; 153():113331. PubMed ID: 35779422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Ann Hepatol; 2024; 29(3):101288. PubMed ID: 38278181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.
    Shao C; Ye J; Li F; Feng S; Wang W; Zhong B
    Dig Liver Dis; 2019 Oct; 51(10):1392-1399. PubMed ID: 30928418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.